Pollard, Rodney P E <br/><br/>
Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.  [electronic resource] 

 -  Annals of the rheumatic diseases  Jan 2013 
 - 146-8 p.  digital 
<br/><br/> Publication Type: Letter; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/annrheumdis-2012-202071  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Antirheumatic Agents--therapeutic use<br/>B-Cell Activating Factor--blood<br/>Double-Blind Method<br/>Enzyme-Linked Immunosorbent Assay<br/>Humans<br/>Rituximab<br/>Sjogren's Syndrome--blood<br/>Tumor Necrosis Factor Ligand Superfamily Member 13--blood